BofA Securities Adjusts Price Target on Ascendis Pharma to $227 From $217, Maintains Buy Rating
Published on 08/08/2025 at 10:07 am EDT

<h3> Latest news about Ascendis Pharma A/S </h3>
<table>
<tbody>
<tr>
<td><a> Ascendis Pharma A/S, Q2 2025 Earnings Call, Aug 07, 2025 </a></td>
<td> Aug. 08</td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Rise Friday </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> Wedbush Adjusts Price Target on Ascendis Pharma to $220 From $212, Maintains Outperform Rating </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> BofA Securities Adjusts Price Target on Ascendis Pharma to $227 From $217, Maintains Buy Rating </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> UBS Adjusts Price Target on Ascendis Pharma to $307 From $306, Maintains Buy Rating </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> RBC Raises Price Target on Ascendis Pharma to $230 From $210, Keeps Outperform, Speculative Risk </a></td>
<td> Aug. 08</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma Q2 Loss Narrows, Revenue Rises </a></td>
<td> Aug. 07</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 </a></td>
<td> Aug. 07</td>
<td> CI </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading </a></td>
<td> Aug. 06</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma Receives US FDA Approval for Skytrofa as Treatment For Adults with Growth Hormone Deficiency </a></td>
<td> Jul. 28</td>
<td> MT </td>
</tr>
<tr>
<td><a> FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency </a></td>
<td> Jul. 28</td>
<td> CI </td>
</tr>
<tr>
<td><a> Ascendis Pharma's Phase 3 Trial of TransCon PTH to Treat Endocrine Disease Shows Sustained Efficacy </a></td>
<td> Jul. 14</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma A/S Announces New Data from Week 156 of its Phase 3 PaTHway Trial Confirms Sustained Response to TransCon PTH Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life </a></td>
<td> Jul. 14</td>
<td> CI </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as ADRs Edge Up in Monday Trading </a></td>
<td> Jul. 14</td>
<td> MT </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading </a></td>
<td> Jul. 09</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data At Endo 2025 </a></td>
<td> Jul. 07</td>
<td> CI </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading </a></td>
<td> Jul. 01</td>
<td> MT </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading </a></td>
<td> Jun. 25</td>
<td> MT </td>
</tr>
<tr>
<td><a> Oppenheimer Raises Price Target on Ascendis Pharma to $224 From $215, Maintains Outperform Rating </a></td>
<td> Jun. 13</td>
<td> MT </td>
</tr>
<tr>
<td><a> Allarity Therapeutics, Inc Announces Changes to Board of Directors </a></td>
<td> Jun. 11</td>
<td> CI </td>
</tr>
<tr>
<td><a> Ascendis Pharma Set to Exceed Q2 Expectations, RBC Says </a></td>
<td> Jun. 10</td>
<td> MT </td>
</tr>
<tr>
<td><a> Ascendis Pharma A/S - Special Call </a></td>
<td> Jun. 09</td>
</tr>
<tr>
<td><a> Ascendis Pharma A/S Announces Week 26 Interim Analysis Results from Its Ongoing Coach Trial </a></td>
<td> Jun. 09</td>
<td> CI </td>
</tr>
<tr>
<td><a> European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading </a></td>
<td> Jun. 02</td>
<td> MT </td>
</tr>
</tbody>
</table>
<a>More news</a>
<a>ASCENDIS PHARMA A/S</a>
<a><h2> Stock </h2></a>
<h2> ASND </h2>
<h2> US04351P1012 </h2>
<table>
<tbody>
<tr>
<td> Market Closed - Nasdaq Other stock markets 04:00:00 2025-08-08 pm EDT </td>
</tr>
<tr>
<td> 191.49 <sup>USD</sup></td>
<td> +0.60% </td>
</tr>
<tr>
<td> 5-day change </td>
<td> 1st Jan Change </td>
</tr>
<tr>
<td> +9.75% </td>
<td> +39.09% </td>
</tr>
</tbody>
</table>
<a> More quotes </a>
<h3><a> Chart </a></h3>
<label>Duration</label>
<select>
<option>Auto.</option>
<option>2 months</option>
<option>3 months</option>
<option>6 months</option>
<option>9 months</option>
<option>1 year</option>
<option>2 years</option>
<option>5 years</option>
<option>10 years</option>
<option>Max.</option>
</select>
<label>Period</label>
<select>
<option>Day</option>
<option>Week</option>
</select>
<a> ASND: Dynamic Chart </a>
<h3> Income Statement and Estimates </h3>
<a> More financial data </a>
<h3><a> Headlines </a></h3>
<a><p><b>Weekly market update: A little respite for investors?</b></p></a>
<a><p><b>Trump appoints Stephen Miran to the Fed and keeps control over Powell's successor</b></p> August 08, 2025 at 10:25 am EDT </a>
<a><p><b>Is The Trade Desk on the road to normalization? </b></p> August 08, 2025 at 10:06 am EDT </a>
<a><p><b>Leverage, buy, repeat: the addiction of crypto treasuries</b></p> August 08, 2025 at 06:18 am EDT </a>
<a>All our articles</a>
<ol>
<a>Stock Market</a>
<a>Stock Market News</a>

BofA Securities Adjusts Price Target on Ascendis Pharma to $227 From $217, Maintains Buy Rating

BofA Securities raised its price target on Ascendis Pharma from $217 to $227 while maintaining a 'Buy' rating. The adjustment follows recent positive earnings reports and FDA approvals for the company's drugs.